AbstractBackgroundDementias and mental health disorders (i.e. depression, anxiety) are significant public health challenges. Chronic consumption of a Mediterranean diet (MD) has been associated with lower incident dementia, improved cognitive performance, and reduced brain atrophy. Yet, short‐term studies and randomised clinical trials (RCT) are lacking. Our systematic review of RCTs showed that in only four available studies, a MD can improve attention, alertness and contentment in up to 10 days (1). In a controlled efficacy study with all foods provided, we aim to explore postprandial, 24‐h and 5 days impacts of a MD and a Western diet (WD) on mood, anxiety and cognition, cerebral blood flow as assessed by MRI.MethodMediMood is an efficacy crossover RCT. Individuals (n = 25) over 18 years with mild to moderate anxiety and/or depression will complete a 5‐day MD and a 5‐day WD intervention with a 4‐week wash‐out period, with foods, meal plans and instructions provided. Biological samples (blood, urine, faeces) will be collected. The primary outcomes are mood and anxiety assessed using Bond‐Lader and POMS questionnaires. Secondary outcomes include cognitive outcomes assessed through computerised neuropsychology tests, brain perfusion assessed by MRI, select cardiometabolic and inflammatory biomarkers, ketones, brain‐derived neurotrophic factor, several hormones (e.g. serotonin, dopamine), gut microbiome speciation, sleep quality and behaviour change. The assessment time points during each arm are baseline (day 1 morning), postprandial (post day 1 lunch), 24‐h (day 2 morning) and day 6 morning.ResultNAConclusionThis will be the first well‐controlled RCT examining the acute and short‐term impacts of a MD and a WD on mental health and cognition in a targeted risk group. MediMood considers interfaces between sleep quality and the gut‐brain axis as modifiable determinants of mental health. We expect the findings to provide novel insights in efficacy of a MD on daily and short‐term well‐being in those with existing mild‐moderate mental health difficulties and to provide an initial mechanistic understanding of any observed benefits. Funding:Medical Research Council (MRC, UK), NuBrain Consortium (MR/T001852/1); Turkish Government personal PhD scholarship
Read full abstract